Resultats de la cerca - Martin Reck

Refinar resultats
  1. 1
    What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

    What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? per Martin Reck

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Implications for Clinical Practice

    Implications for Clinical Practice per Martin Reck

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology

    First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology per Martin Sebastian, Alexander Schmittel, Martin Reck

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer

    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer per Leora Horn, Martin Reck, David R. Spigel

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis

    Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis per Andreas Hermes, U. Gatzemeier, Benjamin Waschki, Martin Reck

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Nivolumab plus ipilimumab in non-small-cell lung cancer

    Nivolumab plus ipilimumab in non-small-cell lung cancer per Martin Reck, Hossein Borghaei, Kenneth J. O’Byrne

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  7. 7
    Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

    Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer per John V. Heymach, David H. Harpole, Martin Reck

    Publicat 2024
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  8. 8
    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects per Solange Peters, Luis Paz‐Ares, Roy S. Herbst, Martin Reck

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

    Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches per Martin Reck, David P. Carbone, Marina Chiara Garassino, Fabrice Barlési

    Publicat 2021
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    Guide to detecting epidermal growth factor receptor (<i>EGFR</i>) mutations in ctDNA of patients with advanced non-small-cell lung cancer

    Guide to detecting epidermal growth factor receptor (<i>EGFR</i>) mutations in ctDNA of patients with advanced non-small-cell lung cancer per Nicola Normanno, Marc G. Denis, Kenneth S. Thress, M. Ratcliffe, Martin Reck

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    Anesthetic Influence on Occurrence and Treatment of the Trigemino-Cardiac Reflex

    Anesthetic Influence on Occurrence and Treatment of the Trigemino-Cardiac Reflex per Cyrill Meuwly, Tumul Chowdhury, Nora Sandu, Martin Reck, Paul Erné, Bernhard Schaller

    Publicat 2015
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  12. 12
    Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression

    Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression per Sebastian Marwitz, Swetlana Scheufele, Sven Perner, Martin Reck, Ole Ammerpohl, Torsten Goldmann

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up per G. D’Addario, Martin Früh, Martin Reck, Pia Baumann, Walter Klepetko, Enriqueta Felip

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

    Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Pati... per Jonathan W. Goldman, Peipei Shi, Martin Reck, Luis Paz‐Ares, Andrew Koustenis, Karla Hurt

    Publicat 2015
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up per Solange Peters, Alex A. Adjei, Cesare Gridelli, Martin Reck, K.M. Kerr, Enriqueta Felip

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up per Martin Reck, Sanjay Popat, Niels Reinmuth, Dirk De Ruysscher, Keith M. Kerr, Solange Peters

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL)

    Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL) per Natasha B. Leighl, Petr Zatloukal, J. Mezger, Rodryg Ramlau, N. Moore, Martin Reck, Christian Manegold

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Small cell lung cancer: a slightly less orphan disease after immunotherapy

    Small cell lung cancer: a slightly less orphan disease after immunotherapy per Jordi Remón, Mihaela Aldea, Benjamin Besse, David Planchard, Martin Reck, Giuseppe Giaccone, Jean‐Charles Soria

    Publicat 2021
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  19. 19
    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts per Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  20. 20
    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? per Sanjay Popat, Christian Grohé, J. Corral, Martin Reck, Silvia Novello, Maya Gottfried, Dejan Radonjic, R. Kaiser

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:

Eines de cerca: